Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.

Bibliographic Details
Published in:Health Technology Assessment
Main Authors: Howard, Dena R, Munir, Talha, McParland, Lucy, Rawstron, Andy C, Chalmers, Anna, Gregory, Walter M, O'Dwyer, John L, Smith, Alison, Longo, Roberta, Varghese, Abraham, Smith, Alexandra, Hillmen, Peter
Format: Text
Language:English
Published: NIHR Journals Library 2017
Subjects:
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494513/
http://www.ncbi.nlm.nih.gov/pubmed/28628003
https://doi.org/10.3310/hta21280
Description
Description not available.